Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. has announced that its application for the clinical trial of HLX17, a pembrolizumab biosimilar for treating various cancers, has been approved by the National Medical Products Administration. HLX17, which mimics the original drug pembrolizumab, has shown similar preclinical pharmacologic properties and could potentially offer alternative treatment options for multiple cancer types. However, the company cautions that the development and commercialization of HLX17 are not guaranteed and advises shareholders and potential investors to trade with caution.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.